UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organizat ...

Group 1 - Zurich Insurance Group has agreed to acquire ClearView Wealth for A$408.3 million (approximately $288.30 million) [1] - ClearView shareholders will receive a cash consideration of 65 Australian cents per share, representing a 21.5% premium to its last closing price [2]

Profitability improved as the company delivered its first full year of positive Adjusted EBITDA. Gross margin was 79% in the fourth quarter and 79.6% for the full year, with Maheshwari noting the full-year gross margin came in about 200 basis points above the company’s original 2025 guidance. He attributed the outperformance to stable average selling prices from favorable procedure mix and to operational initiatives such as supply chain efficiency and cost optimization.For the full year 2025, worldwide reve ...

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnshul Maheshwari - CFO and COOCaitlin Roberts - Director of MedTech Equity ResearchDavid Saxon - Managing DirectorLaura Francis - CEOMathew Blackman - Managing DirectorPatrick Wood - Managing DirectorSaqib Iqbal - VP of FP&A and Investor RelationsTravis Steed - Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to SI-BONE's fourth quarter 2025 earnings co ...

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnshul Maheshwari - CFO and COOCaitlin Roberts - Director of MedTech Equity ResearchDavid Saxon - Managing DirectorLaura Francis - CEOMathew Blackman - Managing DirectorPatrick Wood - Managing DirectorSaqib Iqbal - VP of FP&A and Investor RelationsTravis Steed - Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to SI-BONE's Fourth Quarter 2025 Earnings Co ...

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker5Good afternoon, and welcome to SI-BONE's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Saqib Iqbal, Vice President, FP&A, and Investor Relations at SI-BONE, for a few introductory ...

SI-BONE Corporate Overview Recent Highlights – Record Performance Fourth Quarter 2025 Fiscal Year 2025 Note: Financial As of February 18, 2026 February 2026 Forward-Looking Statements The statements in this presentation regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve signific ...

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior ...

Company Overview - SI-BONE, Inc. is a global leader in developing procedural solutions for clinical challenges related to compromised bone [3] - The company specializes in biomechanical design and innovations specific to anatomy, focusing on spinopelvic anatomy [3] - Since its inception in 2009, SI-BONE has supported over 140,000 procedures, backed by clinical evidence including four randomized controlled trials and over 180 peer-reviewed publications [3] Upcoming Events - SI-BONE will participate in the TD Cowen 46th Annual Health Care Conference in Boston, MA, hosting a fireside chat on March 2, 2026, at 7:30 a.m. Pacific Time [1] - Investors can listen to the conference call by registering through a provided link, with live audio available on the company's website [2]

Core Viewpoint - Si-Bone (SIBN) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, which could significantly influence its stock price based on actual results compared to estimates [1][2]. Financial Expectations - The upcoming earnings report is scheduled for February 23, and a better-than-expected performance could lead to a rise in stock price, while a miss could result in a decline [2]. - The consensus estimate indicates a quarterly loss of $0.13 per share, reflecting an 18.2% decrease year-over-year, with revenues projected at $56.3 million, representing a 14.9% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst assessments during this period [4]. - Si-Bone's Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [8][9]. - Si-Bone currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [11]. Historical Performance - In the last reported quarter, Si-Bone was expected to post a loss of $0.16 per share but achieved a loss of $0.11, resulting in a positive surprise of 31.25% [12]. - Over the past four quarters, Si-Bone has consistently beaten consensus EPS estimates [13]. Conclusion - While Si-Bone does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding this stock ahead of its earnings release [16].